Archive for the 'Determining Efficacy' Category
Studies which measure or otherwise analyze the effectiveness of various treatments and the methods used to generate the information from which efficacy is determined (for instance, is MRI an effective method to measure chemotherapy results).
July 22nd, 2008. A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results
Conclusions: Tetrathiomolybdate has antiangiogenic effects in malignant pleural mesothelioma patients after resection of gross disease, and exhibits minimal toxicity and comparable efficacy to previous multimodality trials. Tetrathiomolybdate should be evaluated for efficacy in combination with standard malignant pleural mesothelioma regimens, as well as for postsurgical maintenance therapy.
July 22nd, 2008. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial
Conclusion: The combination of pemetrexed plus gemcitabine was active in patients with MPeM with a notably high incidence of neutropenia. Median TTPD and OS seem promising. This regimen may provide an alternative to standard therapies, especially for patients who cannot tolerate a platinum-based regimen.
July 18th, 2008. Pemetrexed
Addition of folic acid and vitamin B12 significantly reduced the toxicity of pemetrexed, especially hematologic toxicity and gastrointestinal toxicity. Pemetrexed is the expected agent for use in high risk patients, especially elderly or poor performance status patients.
July 12th, 2008. A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer
Conclusion: At this dose and schedule, L-alanosine was ineffective in patients with advanced MTAP-deficient tumors.
July 11th, 2008. Incidence of atrial fibrillation after extrapleural pneumonectomy versus pleurectomy in patients with malignant pleural mesothelioma
The increased odds of having AF after EPP could be due to right heart stress caused by pneumonectomy. Increased right heart stress might not be sufficient to cause AF alone, but may be an important risk factor that warrants further investigation.
Posted in Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Pleurectomy/decortication, Pneumonectomy, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
July 9th, 2008. A novel combination: ranpirnase and rosiglitazone induce a synergistic apoptotic effect by down-regulating Fra-1 and Survivin in cancer cells
The drug combination does not have a synergistic effect on killing in Fra-1 knockdown cells, showing that Fra-1 modulation accounts in part for the synergism. The novel drug combination of ranpirnase and rosiglitazone is a promising combination to treat cancers with increased PI3K-dependent Fra-1 expression or Survivin.
July 3rd, 2008. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program
Conclusion: This large EAP confirmed the activity of pemetrexed plus cisplatin and pemetrexed plus carboplatin in chemonaive patients with MPM, demonstrating clinically similar time to progressive disease and 1-year survival rates.
July 3rd, 2008. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program
Conclusions: In the present expanded access program, single-agent pemetrexed demonstrated promising activity in MPM in both chemonaïve and pretreated patients, with TTPD of 6.0 and 4.9 months, respectively, 1-year survival >or=54.7%, and mild hematologic toxicity.
July 1st, 2008. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma
Conclusion: Our results show that pleurectomy can be performed as a means of palliation for advanced-stage disease with a low mortality rate and may, in fact, improve survival in patients with epithelial subtype as compared with historical controls in the literature with no surgical intervention.
Posted in Biphasic or Mixed, Determining Efficacy, Epithelioid, Extrapleural Pneumonectomy (EPP), Full Archive, Pleural, Sarcomatoid, Surgery, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 27th, 2008. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
The NSCLC trials include patients with squamous cell histologic features and treated brain metastases, populations for which bevacizumab is currently not indicated. These trials will determine whether cediranib will join the growing armamentarium of therapeutic options for thoracic malignancies and broaden the number of patients with NSCLC who could potentially benefit from antiangiogenic therapy.
June 26th, 2008. Piroxicam and intracavitary platinum-based chemotherapy for the treatment of advanced mesothelioma in pets: preliminary observations
The therapy was able to arrest the effusion in all patients for variable remission times: one dog is still in remission after 3 years, one dog died of progressive disease after 8 months and one cat died due to progressive neoplastic growth after six months, when the patient developed a mesothelial cuirass. The combination showed remarkable efficacy at controlling the malignant effusion secondary to MM in our patients and warrants further investigations.
June 26th, 2008. Induction of apoptosis by intrapleural perfusion hyperthermo-chemotherapy for malignant pleural mesothelioma
Conclusion: In patients with malignant pleural mesothelioma, intrapleural perfusion hyperthermo-chemotherapy induced potent apoptosis of tumor cells, increasing immediately postperfusion and peaking at 24 h.
June 24th, 2008. Multimodal Therapy for Malignant Pleural Mesothelioma Including Extrapleural Pneumonectomy
During the follow-up duration of 23 months, 3 patients (18 %) developed distant metastasis and one (6 %) a mediastinal local recurrence. Multimodal therapy of malignant pleural mesothelioma including extrapleural pneumonectomy should only be performed in specialised centres for thoracic surgery where uncomplicated interdisciplinary communication is the rule and which provide the required expertise in patient selection, operative technique and postoperative care.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, Pemetrexed (Alimta), Radiation, Surgery, Survival, Treatment, Trimodality Therapy, Type of Assessment: | No Comments »
June 24th, 2008. Chemotherapy of malignant pleural mesothelioma: have we made any progress?
Besides first-line therapy, there are also data to support the efficacy of chemotherapy in pretreated patients. In spite of the various results of preclinical trials which support the prognostic significance of certain targeted structures of intra- and intercellular signal transduction, no relevant efficacy could be shown for targeted therapies in mesothelioma up to now.
June 11th, 2008. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
Posted in Carboplatin, Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Immunohistochemistry or IHC, Occupational Asbestos Exposure, PET Scan, Pemetrexed (Alimta), Pleural, Treatment, Type of Assessment: | No Comments »
June 11th, 2008. Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
6%). Cisplatin and intravenous vinorelbine is a highly active regimen in MPM with a response rate and survival comparable to the most active regimens so far reported.
June 6th, 2008. Long-term mortality from pleural and peritoneal cancer after exposure to asbestos: Possible role of asbestos clearance
The risk for pleural cancer, rather than showing an indefinite increase, might reach a plateau when a sufficiently long time has elapsed since exposure. The different trends for pleural and peritoneal cancer might be related to clearance of the asbestos from the workers' lungs.
Posted in Causation, Determining Efficacy, Diagnosis & Differentiation, Epidemiological, Full Archive, Imatinib Mesylate (Gleevec/Glivec), Intraperitoneal Chemotherapy, Occupational Asbestos Exposure, Oxaliplatin (Eloxatin), PET Scan, Pleural, Pleural Catheters, Proton Beam Therapy, Staging, Symptoms & Symptom Management, Treatment, Type of Assessment:, melphalan, paclitaxel | No Comments »
June 4th, 2008. Ranpirnase as a potential antitumor ribonuclease treatment for mesothelioma and other malignancies
Most clinical studies have been conducted in patients with malignant mesothelioma, and a confirmatory Phase IIIb trial is currently underway for the treatment of this disease. Owing to its selective destruction of malignant cells and favorable toxicology profile, ranpirnase is a promising antitumor agent with ideal attributes that are generally lacking in conventional cytotoxic drugs.
June 4th, 2008. Malignant mesothelioma 2008
Novel therapies including intrapleural chemotherapy, photodynamic therapy and hyperthermic perfusion have also been used with some success. Finally there are several attempts at immunomodulating and targeted treatments, which are in phase I/II trials.
Posted in Causation, Chemotherapy, Determining Efficacy, Diagnosis & Differentiation, Full Archive, General, Immune-based Therapies, New & Novel, Occupational Asbestos Exposure, Photodynamic Therapy (PDT), Radiation, SV40, Serum Marker/Blood Test, Survival, Treatment, Type of Assessment: | No Comments »
|
|  |
